The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19

University of California Irvine (UCI)

Status and phase: Withdrawn; Early Phase 1

Conditions: COVID-19

Treatments: Drug: NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)

Study type: Interventional

Funder types: Other

Identifiers

NCT05371288

CCR-21-128

Details and patient eligibility

About

The purpose of this research study is to assess if glutathione, along with NAC (N-acetyl cysteine) and Alpha lipoic acid (ALA), can help reverse some of the COVID long-haul symptoms.Subjects will be randomized in to one of two groups. Depending on the group they are randomized in to, subjects will be taking either a combination of NAC, Alamax CR, and liposomal GSH or the same three nutritional supplements with a multivitamin and magnesium. Regardless of the group, subjects will be asked questions to assess their COVID symptoms, physical and mental health status. They will also be asked to take blood samples.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with positive COVID testing (AB, RT PCR) and mild-severe symptoms based on COVID symptom list

Exclusion criteria

• History of a severe sulfa sensitivity (i.e., anaphylaxis, Stevens Johnson Syndrome), allergy to meat products and/or gelatin (alpha gal allergy) and/or a history of an allergic or adverse reaction to NAC, alpha lipoic acid and/or GSH.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

0 participants in 2 patient groups

No Multivitamin and Magnesium

Experimental group

Description:

Subjects randomized into Group A will take the following amount for 28 days * 4 capsules of NAC (600mg each) once in the morning and once in the evening * 1 tablet (600mg) of Alamax CR once in the morning and once in the evening * 8 capsules (250 mg each) of liposomal GSH in the morning and in the evening

Treatment:

Drug: NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)

Multivitamin and Magnesium

Active Comparator group

Description:

Subjects randomized into Group B will be taking a multivitamin and magnesium for 14 days. Afterwards, they will take the following for 14 days. * 4 capsules of NAC (600mg each) once in the morning and once in the evening * 1 tablet (600mg) of Alamax CR once in the morning and once in the evening * 8 capsules (250 mg each) of liposomal GSH in the morning and in the evening

Treatment:

Drug: NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)